CN110799530A - Hla-g转录物和同种型及它们的用途 - Google Patents

Hla-g转录物和同种型及它们的用途 Download PDF

Info

Publication number
CN110799530A
CN110799530A CN201880041616.XA CN201880041616A CN110799530A CN 110799530 A CN110799530 A CN 110799530A CN 201880041616 A CN201880041616 A CN 201880041616A CN 110799530 A CN110799530 A CN 110799530A
Authority
CN
China
Prior art keywords
leu
ala
glu
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880041616.XA
Other languages
English (en)
Chinese (zh)
Inventor
E·D·卡罗塞拉
戴安娜·特罗尼克-勒·鲁
简-菲利普·戴斯里斯
杰罗姆·韦瑞尼
弗朗索瓦·帝格朗尚
N·鲁阿-弗雷斯
乔尔·勒马约特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Assistance Publique - Hôpitaux de Paris
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Commissariat à l'Énergie Atomique et Aux Énergies Alternatives filed Critical Assistance Publique - Hôpitaux de Paris
Publication of CN110799530A publication Critical patent/CN110799530A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880041616.XA 2017-07-24 2018-07-24 Hla-g转录物和同种型及它们的用途 Pending CN110799530A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305986.6 2017-07-24
EP17305986.6A EP3434688A1 (en) 2017-07-24 2017-07-24 Hla-g transcripts and isoforms and their uses
PCT/EP2018/070061 WO2019020641A1 (en) 2017-07-24 2018-07-24 TRANSCRIPTS AND ISOFORMS OF HLA-G AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN110799530A true CN110799530A (zh) 2020-02-14

Family

ID=59772544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880041616.XA Pending CN110799530A (zh) 2017-07-24 2018-07-24 Hla-g转录物和同种型及它们的用途

Country Status (5)

Country Link
US (1) US11655283B2 (enExample)
EP (2) EP3434688A1 (enExample)
JP (1) JP7271446B2 (enExample)
CN (1) CN110799530A (enExample)
WO (1) WO2019020641A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113249329A (zh) * 2021-04-23 2021-08-13 台州恩泽医疗中心(集团) 表达α1结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
CN113278590A (zh) * 2021-04-23 2021-08-20 台州恩泽医疗中心(集团) 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
CN113528448A (zh) * 2020-04-14 2021-10-22 同济大学 一种人胚胎干细胞的构建方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
US20250297013A1 (en) * 2022-03-25 2025-09-25 Hk Inno.N Corporation Hla-g-specific antibody and use thereof
WO2025101877A1 (en) * 2023-11-08 2025-05-15 The Children's Hospital Of Philadelphia Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091078A2 (en) * 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306913B2 (en) * 2002-12-20 2007-12-11 Applera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof
FR2856599A1 (fr) * 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US10702559B2 (en) * 2016-02-09 2020-07-07 The General Hospital Corporation Methods and compositions relating to engineered microbial cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091078A2 (en) * 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI: "GenBank登录号：AB528641.1" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528448A (zh) * 2020-04-14 2021-10-22 同济大学 一种人胚胎干细胞的构建方法
CN113528448B (zh) * 2020-04-14 2023-01-24 同济大学 一种人胚胎干细胞的构建方法
CN113249329A (zh) * 2021-04-23 2021-08-13 台州恩泽医疗中心(集团) 表达α1结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
CN113278590A (zh) * 2021-04-23 2021-08-20 台州恩泽医疗中心(集团) 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用

Also Published As

Publication number Publication date
EP3434688A1 (en) 2019-01-30
US20200148743A1 (en) 2020-05-14
US11655283B2 (en) 2023-05-23
WO2019020641A1 (en) 2019-01-31
JP2020530978A (ja) 2020-11-05
EP3658579A1 (en) 2020-06-03
JP7271446B2 (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
JP6196338B2 (ja) 診断および治療のための腫瘍関連抗原の同定
EP3802922B1 (en) Novel immune checkpoint inhibitors
US11655283B2 (en) HLA-G transcripts and isoforms and their uses
JP6285472B2 (ja) 診断及び治療のための腫瘍関連マーカーの同定
JP2016179986A (ja) 腫瘍の診断と治療を目的とした表面会合抗原の同定
JP2015525569A (ja) 修飾型自己エピトープに対する抗腫瘍免疫応答
WO2019129892A1 (en) T cell receptors for tumor specific proteasome splice variants and uses thereof
JP2024514477A (ja) Ｓａｒｓ－ｃｏｖ－２抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
EP2298799B1 (en) A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
EP3016973A1 (en) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
CN117500512A (zh) 针对ras衍生的复发性新抗原的t细胞受体及其鉴定方法
NUNES Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm
MX2008003464A (en) Identification of tumor-associated antigens for diagnosis and therapy
HK1165472A (en) In tumours differentially expressed gene products and use of the same
HK1165485A (en) In tumours differentially expressed gene products and use of the same
WO2016042137A1 (en) Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm
HK1165479A (en) In tumours differentially expressed gene products and use of the same
HK1165482A (en) In tumours differentially expressed gene products and use of the same
HK1165467A (en) In tumours differentially expressed gene products and use of the same
HK1165477A (en) In tumours differentially expressed gene products and use of the same
HK1165484A (en) In tumours differentially expressed gene products and use of the same
HK1165473A (en) In tumours differentially expressed gene products and use of the same
HK1206427B (en) Anti-tumour response to modified self-epitopes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200214